And unlike those approaches, GLP-1 therapy under medical supervision has a clinical success rate backed by two decades of research
The main adverse reactions were gastrointestinal side effects, including nausea, diarrhea, and vomiting
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans
Like semaglutide and tirzepatide, it is a glucagon-like peptide-1 (GLP-1) agonist, meaning it acts on GLP-1 receptors just like the natural GLP-1 hormone in your body
105 Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial